Education and Training
IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: TEVAR
- other: Guideline directed medical therapy and surveillance of dissection
Eligibility
Inclusion Criteria:
1. Age > 21 years
2. Stanford type B aortic dissection not involving the aorta at or proximal to the
innominate artery, without rupture and/or malperfusion (renal, mesenteric, or
extremity)
3. Acuity: within 48 hours - 6 weeks of index admission
4. Ability to provide written informed consent and comply with the protocol
Exclusion Criteria:
1. Ongoing systemic infection
2. Pregnant or planning to become pregnant in the next 3 months
3. Life expectancy related to non-aortic conditions < 2 years
4. Unwilling or unable to comply with all study procedures including serial imaging
follow-up
5. Known patient history of genetic aortopathy
6. Penetrating Aortic Ulcer and Intramural hematoma
7. Iatrogenic (traumatic) aortic dissection
8. Previous aortic dissection or aortic surgery
9. Prior aortic aneurysmal disease
Ages Eligible for Study
21 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting